Compare Medpace Holdings Inc (MEDP) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while iShares 10 20 Year Treasury Bond ETF trades at $92.23 (market cap $11.02B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and iShares 10 20 Year Treasury Bond ETF for 60 Days on average.
| MEDP | TLH | |
|---|---|---|
Market Cap | $16.82B | $11.02B |
Volume | 223,093 | 6,609,157 |
Sector | Health | Fixed Income |
52-Week High | $630.19 | $105.36 |
52-Week Low | $393.42 | $91.34 |
Typical Hold Time | 14 Days | 60 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $91.45, down 0.12% with a bearish technical outlook. The ETF has seen unusually high trading volume recently, with 2.3 million shares traded on September 30, 2026. Bond market volatility has driven significant price movements as 10-year Treasury yields reached multi-decade highs above 5% before pulling back. The fund maintains regular dividend distributions, with recent payments ranging from $0.36 to $0.38 per share.
The outlook remains challenging amid persistent bond market volatility and expectations of higher-for-longer interest rates. Rising yields pressure bond prices, creating headwinds for TLH, though current levels may attract income-seeking investors. Key risks include further Fed tightening and inflation concerns, while potential catalysts include economic slowdown or Fed policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
